TJ108

**TJ108** is a bispecific, dual-payload antibody-drug conjugate (ADC) in preclinical development for oncology, primarily non-small cell lung cancer (NSCLC). It is engineered to simultaneously target **epidermal growth factor receptor (EGFR)** and **human epidermal growth factor receptor 3 (HER3)** or, in some conflicting reports, **c-Met** as a secondary target. Its dual-payload design incorporates both a **DNA topoisomerase I inhibitor** and a **microtubule inhibitor**, which are linked to the antibody using a proprietary dual-linker payload (DLP) architecture. The drug aims to deliver two mechanistically distinct cytotoxic payloads to tumors expressing both target antigens, thereby improving efficacy against tumor heterogeneity and drug resistance. The underlying technology leverages bispecific targeting for improved tumor selectivity and a branched-linker architecture for co-delivery of both cytotoxics in a single molecule. Developed by Phrontline Biopharma, TJ108 is partnered globally with Samsung Bioepis for clinical development and commercialization, with an initial focus on solid tumors including NSCLC[1][2][3][4][5].